February 16, 2024

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Completion of US FDA Inspection at synthetic peptide API facility of Auro Peptides Ltd., a subsidiary of the Company – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The manufacturing unit of Auro Peptides Ltd, the synthetic peptides API business arm of the company, situated at Indrakaran Village, Kandi Mandal, Sangareddy District, Telangana, was audited by the US FDA from 12th to 16th February 2024. The inspection was concluded with zero observations.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by BADDIGAM ADI REDDY
Date: 2024.02.16 12:50:24 +05'30'

B. Adi Reddy
Company Secretary